353 related articles for article (PubMed ID: 16508892)
21. Partial agonism and schizophrenia.
Bolonna AA; Kerwin RW
Br J Psychiatry; 2005 Jan; 186():7-10. PubMed ID: 15630117
[No Abstract] [Full Text] [Related]
22. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.
Adan-Manes J; Garcia-Parajua P
J Clin Pharm Ther; 2009 Apr; 34(2):245-6. PubMed ID: 19250146
[TBL] [Abstract][Full Text] [Related]
23. Aripiprazole: pharmacology, efficacy, safety and tolerability.
Kinghorn WA; McEvoy JP
Expert Rev Neurother; 2005 May; 5(3):297-307. PubMed ID: 15938662
[TBL] [Abstract][Full Text] [Related]
24. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.
Ercan ES; Uysal T; Ercan E; Akyol Ardic U
Pharmacopsychiatry; 2012 Jan; 45(1):13-9. PubMed ID: 21993869
[TBL] [Abstract][Full Text] [Related]
25. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G; Carlsson A; Wong DF
Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
[TBL] [Abstract][Full Text] [Related]
27. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
Wood M; Reavill C
Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
[TBL] [Abstract][Full Text] [Related]
28. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
Kasper S; Lerman MN; McQuade RD; Saha A; Carson WH; Ali M; Archibald D; Ingenito G; Marcus R; Pigott T
Int J Neuropsychopharmacol; 2003 Dec; 6(4):325-37. PubMed ID: 14609439
[TBL] [Abstract][Full Text] [Related]
30. New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
Goff DC
Am J Psychiatry; 2008 Aug; 165(8):940-3. PubMed ID: 18676595
[No Abstract] [Full Text] [Related]
31. [Aripiprazole induced Parkinsonism: A case report].
Pasquier de Franclieu S; Germain C; Petitjean F
Encephale; 2009 Oct; 35(5):496-8. PubMed ID: 19853725
[TBL] [Abstract][Full Text] [Related]
32. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
Freeman B; Levy W; Gorman JM
J Psychiatr Pract; 2007 Mar; 13(2):120-4. PubMed ID: 17414690
[No Abstract] [Full Text] [Related]
33. Aripiprazole: a review of its pharmacology and clinical use.
Taylor DM
Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
[TBL] [Abstract][Full Text] [Related]
34. Partial agonists in schizophrenia.
Cousins DA; Young AH
Br J Psychiatry; 2005 Apr; 186():354. PubMed ID: 15802697
[No Abstract] [Full Text] [Related]
35. Hiccups associated with switching from olanzapine to aripiprazole in a patient with paranoid schizophrenia.
Hori H; Nakamura J
Clin Neuropharmacol; 2014; 37(3):88-9. PubMed ID: 24824665
[TBL] [Abstract][Full Text] [Related]
36. Worsening of psychosis in a 30 year old man with undifferentiated schizophrenia.
Ahuja N; Lloyd AJ
Ann Clin Psychiatry; 2008; 20(2):113-4. PubMed ID: 18568584
[No Abstract] [Full Text] [Related]
37. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.
Stahl SM
J Clin Psychiatry; 2001 Dec; 62(12):923-4. PubMed ID: 11780870
[No Abstract] [Full Text] [Related]
38. Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
Lerond J; Lothe A; Ryvlin P; Bouvard S; d'Amato T; Ciumas C; Daléry J; Poulet E; Saoud M
J Clin Psychopharmacol; 2013 Feb; 33(1):84-9. PubMed ID: 23277246
[TBL] [Abstract][Full Text] [Related]
39. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
40. Serotonin receptors: their key role in drugs to treat schizophrenia.
Meltzer HY; Li Z; Kaneda Y; Ichikawa J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
